Takeda and F-star Therapeutics have entered a strategic collaboration and license agreement to develop next-generation multi-specific immunotherapies for cancer, with a potential value of as much as $1 billion.   The two companies will jointly research and develop antibodies for new immuno-oncology targets leveraging F-star’s fully-human Fcab and tetravalent mAb2 platforms.   Takeda will then have an exclusive option to select candidates for further development, with F-star retaining the rig...